ERBB2 and neoplasm: Considering the BRCA patients with low HER2 expression in cluster1 exhibited the best prognosis compared to cluster2 and cluster3, we hypothesized that the tumor-promoting pathways might be inhibit in BRCA with low HER2 expression in cluster1.